Latest News
Biocare Medical Acquires Empire Genomics to Expand Molecular Portfolio with Addition of Biomarker Development
Wednesday 23 November 2022

California-based biotech company Biocare Medical, providing immunohistochemistry and FISH (Fluorescent in situ hybridisation) instrumentation and reagents, has acquired US-based cancer molecular diagnostics company Empire Genomics, to aid in cancer research and diagnostics, the company said.

Terms of the transaction were not disclosed.

Empire Genomics is a premier designer, manufacturer and distributor of a comprehensive menu of clinical and custom-labeled molecular probes, enabling research facilities, clinical laboratories, and biotechnology organisations to advance biomarker research, accelerate diagnoses and improve personalised treatment options for patients battling cancer and other complex diseases.

The acquisition complements Biocare's portfolio of IHC antibodies, molecular menu and advanced automation platforms. The addition of Empire Genomics will enable the acceleration of research and advance cancer diagnostics for better patient outcomes.
Date Published: 23/11/2022